(Adnkronos) - L’azienda farmaceutica Lilly ha organizzato la conferenza stampa “Colite ulcerosa: dai bisogni dei pazienti a nuove prospettive”, una malattia cronica intestinale che colpisce in Italia circa 150.000 persone, con oltre 4000 nuove diagnosi all’anno, nel corso della quale si è sottolineata l’importanza di mirikizumab, primo antagonista dell'interleuchina-23p19 per il trattamento della colite ulcerosa attiva da moderata a grave nei pazienti adulti, la cui rimborsabilità è stata approvata dall’Agenzia Italiana del Farmaco.
Category
🗞
NewsTranscript
00:00The ulcerative colitis is a chronic intestinal disease that affects in Italy about 150,000 people with over 4,000 new diagnoses per year, mainly in young people.
00:16Pathologies like this have a strong impact on the quality of life of those who suffer from it.
00:21It was mentioned during the press conference of the pharmaceutical company Lilly Ulcerative Colitis, from the needs of patients to new prospects, during which it was underlined the importance of Miri Kizumab,
00:33the first antagonist of the Interleukin 23p19 for the treatment of active ulcerative colitis, from moderate to severe, in adult patients, whose reimbursement has been approved by the Italian Pharmaceutical Agency.
00:47It is the first drug of the class that we can use for the management of this type of patients.
00:53It is an innovative drug because it acts on the differentiation of lymphocytes T, it acts quickly and effectively,
01:02especially by intervening on those symptoms such as blood diarrhea and many other drugs, but also the evacuation urgency that has a significant impact on the quality of life of patients.
01:17Miri Kizumab, therefore, as a response to an unmet need, acts on the key symptoms of ulcerative colitis that have a strong impact on the life of patients, including the evacuation urgency.
01:31It is that symptom that relieves the patient at home, in the fear of needing a hygienic service,
01:38and therefore greatly reduces his or her working and productive capacity at an age,
01:45I remember that the age in which patients are most affected is the age range ranging from 20 to 50 years.
01:53So we have a disease that impacts in the phase of greater productivity of each individual subject.
02:01The Director General of Amici Italia Salvo Leone explains the emotional impact of a chronic pathology such as ulcerative colitis.
02:08The word chronic means that those affected by this pathology will clearly have to live with it for life.
02:14They are diseases characterized by a non-visible disability, with very difficult symptoms to tell, with phases of activity and non-activity.
02:22So if I had to describe it with one word, I would say it is like going on a trip with an unpleasant companion hoping that he will always sleep.
02:29They are pathologies that have an emotional impact because clearly the patient tends to isolate himself not only from his own family context, but also from the more external context that surrounds him.
02:40So I am referring to the work environment, but also to the school environment, especially for the younger patients.